Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-recovery-mode-email-service.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-recovery-mode-email-service.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-meta-query.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-meta-query.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/l10n/class-wp-translation-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/l10n/class-wp-translation-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/default-filters.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/default-filters.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-duotone.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-duotone.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-user-query.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-user-query.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/script-loader.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/script-loader.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/media.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/media.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-http.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-http.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-application-passwords.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/class-wp-application-passwords.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-global-styles-revisions-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-global-styles-revisions-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-autosaves-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-autosaves-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-menu-items-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-menu-items-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-font-families-controller.php on line 1

Warning: Uninitialized string offset 0 in /srv/users/amstribuneusr12/apps/berlinverdict-aws/public/wp-includes/rest-api/endpoints/class-wp-rest-font-families-controller.php on line 1
Nascent Biotech – Changing the Biotechnology Industry | Berlin Verdict

Nascent Biotech – Changing the Biotechnology Industry

  • facebook
  • twitter
  • instagram
  • pinterest
  • google-news

Vero Beach, Florida, United States, 28th Aug 2022,  Nascent Biotech is an up-and-coming Biotech industry leader that has developed a proprietary product by the name of Pritumumab (PTB). Pritumumab is an antibody—that naturally occurs within humans—that has been isolated and derived by Nascent Biotech using a groundbreaking contemporary biotechnological framework. Pritumumab has large potential in the cancer industry and can be used in cancer treatment. 

The global brain tumor drug market accounted for ~$3.5 billion in 2022, with a projected growth rate of 7.2%. Biotechnology companies play a pivotal role in our everyday life and have all increased in importance and value following the global shift of COVID-19. Companies such as Nascent Biotech have the ability to eat up a large portion of the market share with their modern techniques and products in the cancer-fighting arena. 

In a statement from Nascent Biotech CEO Sean Carrick, he discusses the current position of Nascent Biotech, and its future potential: “The company is moving forward as expected with our phase I clinical trial. In the process, we are learning a lot about ​​Pritumumab. We believe that, as we progress forward with phase I clinical trails and move into phase II, achievement of our milestones will drive significant value to the company and the shareholders.” With the Pritumumab trials moving forward, now appears to be the perfect time to get a piece of the pie, before the company expands rapidly.

On top of this, the Biotech sector is one of the healthiest and strongest sectors in the modern market. It appears that the sector is going to be growing rapidly in the coming months and years. Investors should explore this area, as it appears to be a very good look to invest in early. Following the current market trends, this stock has the potential to reach $3 per share once the trials go into phase II of the clinical trials, and even more following that. 

ABOUT NASCENT BIOTECH

Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com. Our lead candidate, Pritumumab (PTB), is a monoclonal antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 is being researched.

For further information please visit our website www.nascentbiotech.com

Media Contact

Organization: Nascent Biotech

Contact Person: Alex Jackson (Analyst)

Email: Send Email

State: Florida

City: Vero Beach

Country: United States

Website: http://www.nascentbiotech.com/

The post Nascent Biotech – Changing the Biotechnology Industry appeared first on King Newswire.

Information contained on this page is provided by an independent third-party content provider. Binary News Network and this site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact contact@binarynewsnetwork.com

News

Telr Payment Gateway Announces It Is a Gold Sponsor at Fintech Surge 2022

Dubai, UAE, Sep 30, 2022, ZEXPRWIRE, Telr the award-winning online payment gateway is a gold sponsor at FinTech Surge that is set to take...

Indian Visa For Samoa, San Marino, Slovenia, Seychelles And Sierra Leone Citizens

INDIAN VISA FOR SAMOAN CITIZENS Since 2014, Samoans can apply for Indian visas online through the Indian government. Citizens from more than 169 countries can...

The Emergence of Web Series and the increase of Sexual Harassment at workplaces Targeting docile Women – Dr Alok Chandra

The situation is cause for concern for protagonist of Safe and equal work environment for all   . There has been an increase in the...

Live Music at Sea: How Margaritaville at Sea is Amping Up the Tunes

Music lovers can experience new levels of entertainment and find their groove while cruising the Caribbean. Margaritaville at Sea offers unique shows, round-the-clock music,...

German Market Leader in Developing Individualized Trading Algorithms, YourRoboTrader, Has Expanded into the English-Speaking Market

YourRoboTrader, the most successful company in Germany specializing in the development of individualized trading algorithms, has expanded its business activities into the English market. Munich,...

Important Notice – Anti-Fraud Statement From Bitop

Bitop has received feedbacks from users that recently there were many scammers have created the fake Bitop’s trading platform to exploit victims by copying...

Translingua Launches Professional Translation Services and Birth Certificate Translation Services for USCIS

The newly launched Professional Translation Services offered by Translingua Translations USA include translations for legal, medical, technical, financial, and marketing documents, among others. San Diego, CA,...

Captivating notions on Jakarta’s thriving AI technology vision and its embedding journey to boost its AI capabilities

Jakrata, Indonesia, 15th June 2022, ZEXPRWIRE, The 34th global edition of World AI & RPA Show supported by KORIKA and IAIS concluded with 2...